PHR — Phreesia, Inc. · 2026-09-06 · Verdict: WATCH · Conviction 3

Price $10.94 (screen row; last close 2026-09-04, no live quote) · Mkt cap $678.7M (62.04M shares) · EV ~$670.5M (corrected) · EV/guided FY27 adj EBITDA 5.2x · EV/(adj EBITDA less SBC) ~8.4x · FCF yield 9.9% (TTM) · Net cash $8.2M · ADV $9.2M Sources read: 10-K 2026-03-31 (Items 1, 1A, 7), 10-Q 2026-09-03, DEF 14A 2026-05-14, 8-Ks 2026-04-03 (with Q4 FY26 call transcript), 2026-05-04, 2026-05-11, 2026-05-27, 2026-09-02 (Q2 FY27 letter), Form 4s. No Q2 FY27 transcript filed.

1. What the business actually does

Phreesia sells patient intake software to ambulatory practices, health systems and hospitals, then monetises the traffic three ways: subscription software (41% of Q2 FY27 revenue), payment solutions (30%, card processing plus patient financing via AccessOne since November 2025), and network solutions (30%, sponsored patient and provider education sold to life sciences companies per engagement). It handled about 180 million patient visits in 2025, one in six US ambulatory visits (10-K 2026, Item 1).

2. Why it is mispriced — the edge case

This is growth-holder rotation, not a hidden asset. On March 30, 2026 management cut FY27 revenue guidance from $545-559M to $510-520M because pharmaceutical sponsors pulled second-half commitments. The CFO named them: "vaccine spending and targeted marketing around that has pulled back" and "public health with agencies in the federal government" (Q4 FY26 call, CFO Gandhi). Separately, management stopped pushing subscription pricing, so subscription revenue now declines outright, down 2% in Q2 and for the half (10-Q 2026-09-03). Within six months a company priced as compounding SaaS reported flat organic revenue, a guidance cut and acquisition-sourced growth. Growth mandates do not hold that, hence 61% off the 52-week high. That seller is indifferent rather than wrong. The bet is that the network air pocket is a policy cycle, not a permanent reset, and that is not yet observable, hence WATCH.

3. Unit economics and growth

Q2 FY27 revenue was $129.5M, up 10%, but composition matters: payment solutions grew 36% almost entirely on AccessOne, network solutions grew 9%, subscription fell 2% (10-Q). Guidance assumes about $37M of AccessOne contribution (8-K 2026-09-02), so the organic business is roughly flat. AHSCs grew 6% to 4,744 but only 1% sequentially (Q2 FY27 letter). Gross margin is compressing on mix, 66.7% against 68.0% a year ago, because payment solutions carries roughly 38% gross margin against about 79% for subscription and network combined. Every operating expense line fell: GAAP operating income was $7.6M against a $1.5M loss, adjusted EBITDA $32.9M against $22.1M, helped by a May 2026 cut of about 220 positions (10-Q). Margin expansion is cost-out, not leverage on growth.

4. Balance sheet and capital allocation

The screen row understates leverage: it tagged only $1.1M of long-term debt. At July 31, 2026 debt and finance leases were $66.4M, $60.7M of it drawn on a $275M Capital One revolver maturing March 2031, against $74.6M of cash (8-K 2026-09-02). Net cash is $8.2M, not $73.5M. Off balance sheet, a $300M PNC securitisation funds AccessOne, and an April 30, 2026 amendment made Phreesia a co-guarantor of AccessOne MedCard's obligations while loosening covenants to fund non-investment-grade providers (Q1 FY27 letter).

Capital allocation is where conviction breaks. A 2.5 million share repurchase authorisation has existed since March 12, 2025 (10-K 2026, Item 1A) and management has twice named buybacks a priority, yet the only treasury activity in the half was $1.1M of tax withholding (10-Q). Issued shares went from 62.02M to 63.52M in six months, and on September 1, 2026, the day before earnings, the company granted 1,325,000 shares to seven officers including 500,000 to the CEO, another 2.1% in one day (Form 4s, 2026-09-03). Insiders bought nothing on the open market in twelve months. CEO Indig holds 2.9%, Pale Fire Capital 14.4% on a Schedule 13D (DEF 14A 2026-05-14).

5. Management: said versus did

They delivered on costs: FY26 hit its milestones of over $100M adjusted EBITDA and a first year of positive GAAP net income (Q4 FY26 call, CEO Indig), and they held the $125-135M FY27 EBITDA range through a $35M revenue cut. They missed on revenue, and have not repurchased a share under an authorisation they keep citing. $100 invested at the start of FY2022 was worth $20.57 at FY2026 year-end against $160.68 for peers (DEF 14A 2026-05-14).

6. Valuation

TTM free cash flow is $67.5M, a 9.9% yield, but TTM stock compensation is $59.4M and shares grow about 5% a year. Guided FY27 adjusted EBITDA of $130M less roughly $48M run-rate SBC, $24M capex, $4M cash interest and $8M cash taxes leaves about $46M of owner earnings, a 6.8% yield on the $670M enterprise value. Cases run to FY28 on EBITDA net of SBC.

Base (50%): network holds near $140M, subscription flat, payments up 15%; revenue $535M, EBITDA $145M less $45M equals $100M, at 9x gives $14.60. Bear (30%): vaccine and public-health sponsorship stays out; network falls to $115M, subscription down 3%; revenue $500M, EBITDA $115M less $45M equals $70M, at 7x gives $8.00. Bull (20%): ProviderConnect and AccessOne cross-sell land; revenue $580M, EBITDA $170M less $45M equals $125M, at 12x gives $24.00. Probability weighted $14.50 against $10.94, 33% upside with a bear 27% lower.

Reverse DCF: at $10.94 and a 10% required return, the price implies roughly 3% perpetual growth in that $46M of owner earnings, cleared only if network stops shrinking.

7. Catalysts and timeline

Q3 FY27 results around early December 2026 are the first hard read on the second-half network commitments management called low-visibility, and where FY28 gets framed. At roughly $14M of quarterly free cash flow the revolver clears by mid-FY28, when a buyback becomes credible.

8. Risks and pre-registered kill criteria

Network solutions is per-engagement and must be resold annually with no renewal obligation (10-K 2026, Item 1A), mix shift to payments structurally lowers gross margin, and Phreesia now guarantees consumer lending exposure to weaker providers. Kill criteria: 1. Network solutions revenue declines year over year in two consecutive quarters (it grew 9% in Q2 FY27). 2. FY27 adjusted EBITDA guidance is cut below $125M at the Q3 or Q4 report. 3. Diluted share count rises more than 5% year over year, or FY27 closes with zero repurchases under the 2.5M authorisation below $15. 4. Payment solutions revenue rate falls below 2.0% for two consecutive quarters, or PNC covenant relief is sought.

9. Verdict and one-paragraph summary

WATCH, conviction 3. Phreesia is a real business at 5.2x guided EBITDA with positive GAAP net income, $67M of trailing free cash flow and a roughly net-cash balance sheet, and the reason it is down 61% is identifiable and possibly temporary: pharmaceutical sponsors, specifically vaccine and federal public-health budgets, pulled second-half commitments and forced a 7% guidance cut in March 2026. What stops it being an IDEA is that both organic lines are flat or shrinking, all reported growth comes from a $164M acquisition, and $48M to $59M of annual stock compensation plus a 1.325 million share grant the day before earnings consumes most of the free cash flow while a 2.5 million share buyback sits unused. Owner earnings of about $46M are a 6.8% enterprise yield, so the price already assumes network stabilises. Buy the recovery when network grows again, not before.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.